477 related articles for article (PubMed ID: 34472683)
1. MAFLD: Renovation of clinical practice and disease awareness of fatty liver.
Kawaguchi T; Tsutsumi T; Nakano D; Torimura T
Hepatol Res; 2022 May; 52(5):422-432. PubMed ID: 34472683
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
3. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
4. Hepatologists' awareness and knowledge toward NAFLD and the familiarity with renaming from NAFLD to MAFLD.
Alem SA; Fouad Y; AbdAllah M; Attia D; Kamal I; Said E; Gomaa A; Abd-Elsalam SM; Gaber Y
Endocr Metab Immune Disord Drug Targets; 2022 Oct; ():. PubMed ID: 36306455
[TBL] [Abstract][Full Text] [Related]
5. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
7. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
[TBL] [Abstract][Full Text] [Related]
8. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
[TBL] [Abstract][Full Text] [Related]
9. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
10. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
[TBL] [Abstract][Full Text] [Related]
12. Comparison of MAFLD and NAFLD Characteristics in Children.
Xing Y; Fan J; Wang HJ; Wang H
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980118
[TBL] [Abstract][Full Text] [Related]
13. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
14. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
[TBL] [Abstract][Full Text] [Related]
16. Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol-related liver disease.
Vanlerberghe BTK; van Malenstein H; Sainz-Bariga M; Jochmans I; Cassiman D; Monbaliu D; van der Merwe S; Pirenne J; Nevens F; Verbeek J
Clin Transplant; 2023 Jun; 37(6):e14965. PubMed ID: 36940254
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
18. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
19. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies.
Qu W; Ma T; Cai J; Zhang X; Zhang P; She Z; Wan F; Li H
Front Med (Lausanne); 2021; 8():761538. PubMed ID: 34746195
[TBL] [Abstract][Full Text] [Related]
20. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
